We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Validation Study
Psychometric properties of the Spanish version of the screening scale for DSM-IV Generalized Anxiety Disorder of Carroll and Davidson.
INTRODUCTION: The aim was to validate the Spanish version of the screening scale for DSM-IV General Anxiety Disorder of Carroll and Davidson for use in research and clinical practice in Spain for screening and assessing specific anxiety symptoms of patients with Generalized Anxiety Disorder (GAD).
METHODS: Observational, prospective, multisite, study comparing between patients with DSM-IV diagnosis of GAD (group A), starting or switching treatment (group A1) or stable patients (group A2), followed-up for 6 months (group A1) or 2 weeks (group A2) versus healthy control subjects (group B), assessed in a single visit.
RESULTS: Among 223 valuable subjects the scale showed: a) adequate feasibility with a mean time of administration: 6.53 and 4.49 min (TD: 5.48 and 3.56) in groups A and B, and percentage of patients without response <5 %; b) adequate reliability (Kuder-Richardson coefficient: 0.85 and 0.79 in groups A1 and A2, and CCI coefficient: 0.89 in group A2); c) adequate validity, showing capability for discriminating between patients and controls, with area under curve AUC: 0.9713 (IC 95 %: 0.9510-0.9917), and obtaining a high correlation with HARS (r=0.88) and CGI-G (r=0.87) scales, y d) adequate sensitivity to clinical changes from start and end of treatment (SES: -1.6, -3.1 and -3.8 after 1, 3 and 6 months), spite of the high percentage of patients with highest score in group A1 (38.6 %).
CONCLUSION: The Spanish version of the screening scale for DSM-IV GAD showed adequate psychometric properties for use in research and clinical practice in Spain as well as an screening as evaluative measure for patients with GAD, spite of the ceiling effect showed in severe patients.
METHODS: Observational, prospective, multisite, study comparing between patients with DSM-IV diagnosis of GAD (group A), starting or switching treatment (group A1) or stable patients (group A2), followed-up for 6 months (group A1) or 2 weeks (group A2) versus healthy control subjects (group B), assessed in a single visit.
RESULTS: Among 223 valuable subjects the scale showed: a) adequate feasibility with a mean time of administration: 6.53 and 4.49 min (TD: 5.48 and 3.56) in groups A and B, and percentage of patients without response <5 %; b) adequate reliability (Kuder-Richardson coefficient: 0.85 and 0.79 in groups A1 and A2, and CCI coefficient: 0.89 in group A2); c) adequate validity, showing capability for discriminating between patients and controls, with area under curve AUC: 0.9713 (IC 95 %: 0.9510-0.9917), and obtaining a high correlation with HARS (r=0.88) and CGI-G (r=0.87) scales, y d) adequate sensitivity to clinical changes from start and end of treatment (SES: -1.6, -3.1 and -3.8 after 1, 3 and 6 months), spite of the high percentage of patients with highest score in group A1 (38.6 %).
CONCLUSION: The Spanish version of the screening scale for DSM-IV GAD showed adequate psychometric properties for use in research and clinical practice in Spain as well as an screening as evaluative measure for patients with GAD, spite of the ceiling effect showed in severe patients.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app